integrated assessment to Ozanimod in multiple sclerosis
Multidimensional integrated assessment of neurological and immunological patterns to test the efficacy and response to Ozanimod in multiple sclerosis
What was tested
Treatment tested
- Ozanimod
Sphingosine 1-phosphate receptor 5 modulator
What it measured
Main measures
To evaluate the innate immune mediated inflammation in MS patients and to
Other measures (1)
To observe the effect of Ozanimod on innate and adaptive immune cells in terms of
Immune response
Loading reviews and guidelines…
Related trials
- VOYAGE
Phase 3 · Not yet recruiting
Still running
- TG1101-RMS-PED304
Phase 2 / Phase 3 · Recruiting
Still running
- IM047-050
Phase 3 · Recruiting
Still running
- COAST
Phase 4 · Recruiting
Still running
- Assessing the Cognitive Benefits of Ozanimod and Their Br…
Phase 4 · Withdrawn
Stopped early
- A Study to Assess the Effectiveness and Safety of Ozanimo…
Phase 4 · Running, not recruiting
Still running
History
- In scope changed from true to false
Started
Sept 2022
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error